TREATMENT OF ELBOW DYSPLASIA IN DOGS WITH CANINE STEM CELLS

Dr Melissa MacIver

Purpose of the Clinical Study

Joint inflammation and associated diseases are common in dogs, with around 20% of dogs developing osteoarthritis (OA). Large to giant breed dogs are often diagnosed with elbow dysplasia (ED), which can lead to OA later in life. Current treatments, such as medications (non-steroidal anti-inflammatories (NSAIDs)) and surgery, might not work for all dogs. Mesenchymal stromal cells (MSCs) have shown anti-inflammatory effects and could be a treatment option for immune and inflammatory disorders in dogs, like ED. This alternative may have better safety and efficacy and require less owner compliance compared to NSAIDs.

Is Your Pet Eligible?

Dogs that have a confirmed diagnosis of bilateral ED and are otherwise healthy.

Visits/Samples Required

At least 3 visits will be required for this study with a follow up period up to 5 months. Blood, urine and joint fluid samples will be collected for this study. In addition, you will need to complete a Liverpool Osteoarthritis in Dogs (LOAD) questionnaire 12 and 18 weeks following treatment.

Financial Incentives

The costs associated with visit fees, bloodwork, gait analysis, CT, joint tap and joint injections will be covered by the study. This study is generously sponsored by:

eQcell One-Health Since 2010

University of Guelph

Ontario Veterinary College

Clinical Trials

Questions about this study?
Please contact:
ovc.clinicaltrials@uoguelph.ca